CHILDREN'S ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1989.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
Children's Advil is an oral ibuprofen suspension indicated for fever reduction and pain relief in pediatric patients. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce prostaglandin synthesis. This formulation is specifically designed for pediatric dosing and administration.
With LOE approaching and moderate competitive pressure (30/100), brand teams face declining market opportunity and likely workforce realignment toward transition planning or portfolio exit strategies.
Cyclooxygenase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on CHILDREN'S ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moGSK is hiring 4 roles related to this product
Children's Advil represents a declining OTC brand with minimal linked job openings and limited career advancement potential. Assignment to this product typically signals maintenance-mode responsibilities rather than strategic growth opportunities within GSK's portfolio.